Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Reports 2.3 Percent Organic Revenue Growth in Q1 05

Sigma-Aldrich this week reported organic revenue growth of 2.3 percent, which came in at $400 million, for the quarter ending March 31.

The company's January acquisition of cell culture provider JRH contributed an additional 3.2 percent of revenue growth, and currency-exchange benefits provided another 3.1 percent of growth as overall sales increased in the US and in non-European markets, the company said in a statement. Reduced demand for cell culture and analytical products from the reagent producer affected sales in Europe, the company said.

The company reported a 9-percent increase on an R&D spend of $11.7 million in the period and net income improved 19 percent to $74.6 million.

Sigma had $164 million in cash and cash equivalents on hand as of March 31.

Sigma said the amount it attributed to the JRH acquisition increased to $377.7 million, from the previously reported price of $370 million, to meet the terms of a three-year financing arrangement (see BCW 3/3/2005), and to purchase Proligo, a transaction that closed at the start of the second quarter.

— Mo Krochmal ([email protected])

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.